NTRA
Natera, Inc. Common Stock
$331.83
장중 · Vol 95.3K · 52주 $157.43–$343.18 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $316.46 · Aug 31, 2026
NTRA 가격 추세
종가
$316.46
시가
$320.41
고가
$325.65
저가
$316.00
30초 브리핑
NTRA 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 94%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E -3609.4배
업종 피어 비교 전에는 고평가·저평가를 단정하기 어렵습니다.
20일 평균의 1.1배
거래량은 최근 평균 범위입니다.
2026-11-05
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
NTRA 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
13011 McCallen Pass · Austin, TX, United States · 직원 6,135명
시가총액
$46.41B
Trailing P/E
—
최근 12개월 이익 기준
Forward P/E
-3609.4
EPS (TTM)
$-1.32
배당 수익률
—
배당성향
0.0%
베타
1.51
시장보다 민감
ROE
-12.5%
P/B
25.39
EV/EBITDA
-205.8
52주 범위
$157.43 – $343.18
현재 위치 94%
거래량
1.22M
20일 평균 1.13M · 1.1배
애널리스트 의견
매수 86%
총 22명 · 0m
DITM LEAPS Analysis
NTRA 장기 DITM 콜옵션을 진입 적합도 순으로 비교
해당 종목의 옵션 데이터가 없습니다.
재무제표
NTRA 연간 손익·현금흐름·재무상태
매출 성장률
+35.9%
최근 연간 YoY
EPS 성장률
+0.7%
최근 연간 YoY
영업이익률
-13.4%
최근 연간
FCF 마진
3.3%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $2.31B+35.9% | $1.70B+56.7% | $1.08B+32.0% | $820.22M |
| 매출총이익 | $1.49B+45.9% | $1.02B+107.6% | $492.74M+35.4% | $363.97M |
| 영업이익 | -$309.91M-39.4% | -$222.29M+50.2% | -$446.25M+17.5% | -$541.04M |
| 순이익 | -$208.16M-9.3% | -$190.43M+56.2% | -$434.80M+20.6% | -$547.80M |
| 희석 EPS | $-1.52+0.7% | $-1.53+59.5% | $-3.78+32.1% | $-5.57 |
| EBITDA | -$220.54M-48.9% | -$148.08M+62.8% | -$397.80M+23.6% | -$520.80M |
| 영업현금흐름 | $215.30M+58.7% | $135.66M+154.9% | -$246.96M+42.8% | -$431.50M |
| 잉여현금흐름 | $76.11M+29.6% | $58.75M+120.5% | -$286.15M+40.3% | -$479.20M |
| 총자산 | $2.40B+44.4% | $1.66B+15.2% | $1.44B+3.4% | $1.39B |
| 총부채 | $214.38M+14.6% | $187.12M-57.7% | $441.99M-0.9% | $446.22M |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
NTRA 실적·배당 일정
매출 하단
$676.93M
EPS 하단
$-0.61
매출 상단
$720.00M
실적 발표일
2026-11-05
D-65
EPS 상단
$0.13
매출 컨센서스
$706.86M
EPS 컨센서스
$-0.24
뉴스
NTRA 관련 최신 기사
일반3 Momentum Stocks to Own for Decades
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
StockStory · Aug 31, 2026
제품·기술Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
The billionaire has good reasons to like this genetic testing leader.
Motley Fool · Aug 29, 2026
제품·기술Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Zacks · Aug 28, 2026
제품·기술3 Healthcare Stocks with Promising Prospects
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.
StockStory · Aug 27, 2026
일반How Investors May Respond To Natera (NTRA) New MRD Trial Deal And Duquesne Stake Expansion
Natera recently announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers, expanding the use of its technology in oncology research. At the same time, Duquesne Family Office significantly increased its position in Natera, making the diagnostics company its largest healthcare holding and underscoring rising institutional interest in its MRD and medtech platform. Now we’ll explore how this...
Simply Wall St. · Aug 27, 2026
- 일반
Natera (NTRA) Supplies MRD Assay For Phase 1 Skin Cancer Immunotherapy Trial
Natera (NasdaqGS:NTRA) announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers. The Latitude assay will be used to monitor minimal residual disease and treatment response in patients receiving Kupando's investigational therapy. The partnership expands Natera's presence in oncology clinical trials and supports use of its MRD technology across different tumor types. This kind of cancer trial...
Simply Wall St. · Aug 26, 2026
제품·기술Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Duquesne Family Office has beefed up its healthcare holdings.
Motley Fool · Aug 26, 2026
실적VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Zacks · Aug 25, 2026
제품·기술What Is Really Moving Tempus AI Stock Right Now?
While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.
Trefis · Aug 24, 2026
규제·법률Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.
Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks.
Motley Fool · Aug 24, 2026
홀더
NTRA 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
96.7%
기관 보유 (유동주식)
99.6%
내부자 보유
2.9%
기관 수
1,180
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | 12.87M | $4.14B | 8.9% | -3.9% | Jun 30, 2026 |
| Blackrock Inc. | 10.91M | $3.51B | 7.6% | 2.2% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 9.02M | $2.90B | 6.3% | -26.0% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 6.23M | $2.01B | 4.3% | 3.7% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 5.78M | $1.86B | 4.0% | 2.4% | Jun 30, 2026 |
| FMR, LLC | 5.45M | $1.76B | 3.8% | 113.4% | Jun 30, 2026 |
| Wellington Management Group, LLP | 4.04M | $1.30B | 2.8% | -15.3% | Jun 30, 2026 |
| State Street Corporation | 3.66M | $1.18B | 2.5% | 7.0% | Jun 30, 2026 |
| Duquesne Family Office Llc | 3.19M | $1.03B | 2.2% | 4.0% | Jun 30, 2026 |
| Geode Capital Management, LLC | 2.75M | $885.39M | 1.9% | -0.9% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.